Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.
The pharmacokinetics of iproplatin, a quadrivalent second-generation platinum complex the dose-limiting toxicity of which is myelosuppression, was studied in patients with different degrees of renal function impairment. The drug was administered in a 30-min i.v. infusion. The plasma decay of iproplatin was biphasic, with an overall median terminal phase half-life of 3.16 +/- 2.6 (SD) h. The overall mean volume of distribution (Vss) was 39.9 +/- 25.0 liters, with a total body clearance of 14.25 +/- 3.99 liters/h. The total body clearance of iproplatin showed a linear correlation, with renal function measured as creatinine clearance. The toxicity of the drug, expressed as percentage of reduction in platelet count, correlated linearly with the area under the concentration X time curve.
D000970:Antineoplastic Agents / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008657:Metabolic Clearance Rate; D009944:Organoplatinum Compounds / Q000378:metabolism* / Q000633:toxicity
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin; D003404:Creatinine